Blog
RSS FeedPosted by Michael Wonder on 22 Jan 2020
Supporting innovative medicines funding in Scotland
21 January 2020 - Scotland receives superb value from the latest medicines and vaccines thanks to robust measures which ensure ...
Posted by Michael Wonder on 13 Jan 2020
SMC - January 2020 decisions
13 January 2020 - Medicines which can be used to treat prostate cancer, primary progressive multiple sclerosis, a rare form ...
Posted by Michael Wonder on 12 Dec 2019
NICE and the SMC have published recommendations on Shionogi’s Mulpleo (lusutrombopag), approving its use for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
12 December 2019 - Mulpleo (lusutrombopag) is the first licensed treatment to be made available through the National Health Service ...
Posted by Michael Wonder on 10 Dec 2019
Ovarian cancer drug olaparib approved in Scotland as new treatment
9 December 2019 - A maintenance treatment for patients with advanced ovarian cancer has been approved for use in Scotland. ...
Posted by Michael Wonder on 09 Dec 2019
SMC - December 2019 decisions
9 December 2019 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...
Posted by Michael Wonder on 11 Nov 2019
Breast and kidney cancer drugs get approval for use across Scotland's NHS
11 November 2019 - Medicines for breast and kidney cancers are among five new drugs which can now be used ...
Posted by Michael Wonder on 11 Nov 2019
SMC - November 2019 decisions
11 November 2019 - A medicine used to treat advanced breast cancer has today been accepted by the SMC for ...
Posted by Michael Wonder on 08 Oct 2019
AbbVie’s Skyrizi (risankizumab) accepted for use within NHS Scotland
7 October 2019 - SMC recommendation based on results from four pivotal Phase 3 studies, UltIMMa-1, UltIMMa-2, IMMvent and IMMhance evaluating ...
Posted by Michael Wonder on 07 Oct 2019
SMC - October 2019 decisions
7 October 2019 - Medicines which can be used to treat lymphoma, lung cancer, breast cancer and psoriasis have today been ...
Posted by Michael Wonder on 13 Sep 2019
Vertex announces new access agreement with Scottish Government for Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor)
12 September 2019 - Eligible patients in Scotland will immediately have access to Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) in combination with ...
Posted by Michael Wonder on 12 Sep 2019
SMC U-turn for Vertex’s CF drugs
12 September 2019 - Vertex has announced that following a change of heart by the SMC, eligible cystic fibrosis patients ...
Posted by Michael Wonder on 09 Sep 2019
SMC - September 2019 decisions
9 September 2019 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...
Posted by Michael Wonder on 13 Aug 2019
Scottish Medicines Consortium accepts Buvidal for treatment of opioid dependence
13 August 2019 - The Scottish Medicines Consortium has accepted weekly and monthly Buvidal for treatment of opioid dependence in ...
Posted by Michael Wonder on 12 Aug 2019
‘Not acceptable’ disappointment as cystic fibrosis drug not approved in Scotland
12 August 2019 - People with cystic fibrosis in Scotland will continue to be denied potentially life-extending drugs after they ...
Posted by Michael Wonder on 12 Aug 2019
Cystic fibrosis drugs rejected for use by NHS in Scotland
12 August 2019 - Two "life-changing" cystic fibrosis drugs have been rejected for routine use by the NHS in Scotland. ...